0.59(1.63%) Volume: 533,834 10:01AM EST| Market Cap : 50.84 B | Enterprise Value : 57.3 B | P/E (TTM) : 78.17 | P/B : 6.14 |
|---|
BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.03 |
NYSE:BSX's Cash-to-Debt is ranked lower than
98% of the 330 Companies in the Global Medical Devices industry. ( Industry Median: 2.32 vs. NYSE:BSX: 0.03 ) Ranked among companies with meaningful Cash-to-Debt only. |
NYSE:BSX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.15 Max: 4.69 Current: 0.03 |
| Equity-to-Asset | 0.41 |
NYSE:BSX's Equity-to-Asset is ranked lower than
86% of the 309 Companies in the Global Medical Devices industry. ( Industry Median: 0.63 vs. NYSE:BSX: 0.41 ) Ranked among companies with meaningful Equity-to-Asset only. |
NYSE:BSX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18 Med: 0.51 Max: 0.83 Current: 0.41 |
| Debt-to-Equity | 0.80 |
NYSE:BSX's Debt-to-Equity is ranked lower than
84% of the 220 Companies in the Global Medical Devices industry. ( Industry Median: 0.30 vs. NYSE:BSX: 0.80 ) Ranked among companies with meaningful Debt-to-Equity only. |
NYSE:BSX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.54 Max: 3.64 Current: 0.8 |
| Debt-to-EBITDA | 3.06 |
NYSE:BSX's Debt-to-EBITDA is ranked lower than
67% of the 158 Companies in the Global Medical Devices industry. ( Industry Median: 1.98 vs. NYSE:BSX: 3.06 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
NYSE:BSX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -88.33 Med: 3.64 Max: 37.25 Current: 3.06 |
| Interest Coverage | 7.19 |
NYSE:BSX's Interest Coverage is ranked lower than
82% of the 212 Companies in the Global Medical Devices industry. ( Industry Median: 66.37 vs. NYSE:BSX: 7.19 ) Ranked among companies with meaningful Interest Coverage only. |
NYSE:BSX'
s Interest Coverage Range Over the Past 10 Years
Min: 2.47 Med: 3.51 Max: 7.19 Current: 7.19 |
| Piotroski F-Score: 6 |
|
| Altman Z-Score: 2.60 |
|
| Beneish M-Score: -2.46 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | 17.33 |
NYSE:BSX's Operating Margin % is ranked higher than
78% of the 312 Companies in the Global Medical Devices industry. ( Industry Median: 1.96 vs. NYSE:BSX: 17.33 ) Ranked among companies with meaningful Operating Margin % only. |
NYSE:BSX'
s Operating Margin % Range Over the Past 10 Years
Min: 12.22 Med: 13.1 Max: 17.33 Current: 17.33 |
| Net Margin % | 6.93 |
NYSE:BSX's Net Margin % is ranked higher than
50% of the 312 Companies in the Global Medical Devices industry. ( Industry Median: 1.40 vs. NYSE:BSX: 6.93 ) Ranked among companies with meaningful Net Margin % only. |
NYSE:BSX'
s Net Margin % Range Over the Past 10 Years
Min: -56.12 Med: -2.45 Max: 6.93 Current: 6.93 |
| ROE % | 8.89 |
NYSE:BSX's ROE % is ranked higher than
51% of the 304 Companies in the Global Medical Devices industry. ( Industry Median: 0.95 vs. NYSE:BSX: 8.89 ) Ranked among companies with meaningful ROE % only. |
NYSE:BSX'
s ROE % Range Over the Past 10 Years
Min: -44.65 Med: -2.79 Max: 8.89 Current: 8.89 |
| ROA % | 3.46 |
NYSE:BSX's ROA % is ranked higher than
52% of the 332 Companies in the Global Medical Devices industry. ( Industry Median: -0.26 vs. NYSE:BSX: 3.46 ) Ranked among companies with meaningful ROA % only. |
NYSE:BSX'
s ROA % Range Over the Past 10 Years
Min: -21.16 Med: -1.04 Max: 3.46 Current: 3.46 |
| ROC (Joel Greenblatt) % | 81.63 |
NYSE:BSX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 327 Companies in the Global Medical Devices industry. ( Industry Median: 3.87 vs. NYSE:BSX: 81.63 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
NYSE:BSX'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7 Med: -14.88 Max: 81.63 Current: 81.63 |
| 3-Year Revenue Growth Rate | 5.20 |
NYSE:BSX's 3-Year Revenue Growth Rate is ranked higher than
52% of the 254 Companies in the Global Medical Devices industry. ( Industry Median: 4.30 vs. NYSE:BSX: 5.20 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
NYSE:BSX'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5 Med: 4.9 Max: 29 Current: 5.2 |
| 3-Year EBITDA Growth Rate | 64.10 |
NYSE:BSX's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 232 Companies in the Global Medical Devices industry. ( Industry Median: 7.50 vs. NYSE:BSX: 64.10 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
NYSE:BSX'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: 13.15 Max: 83.1 Current: 64.1 |
| John Hussman 50,000 sh (New) David Carlson 750,000 sh (New) Paul Tudor Jones 195,667 sh (New) Caxton Associates 44,975 sh (New) Ray Dalio 176,079 sh (New) Vanguard Health Care Fund 40,024,604 sh (+0.84%) Joel Greenblatt 503,669 sh (+1658.44%) David Tepper 4,782,683 sh (+27.44%) PRIMECAP Management 43,877,562 sh (+4.05%) Diamond Hill Capital 3,024,204 sh (+0.48%) | Michael Price 284,200 sh (unchged) | Steven Cohen Sold Out Julian Robertson Sold Out Dodge & Cox 253,355 sh (-16.21%) Jim Simons 1,146,305 sh (-43.04%) Pioneer Investments 854,578 sh (-54.18%) Mario Gabelli 452,909 sh (-14.20%) Eaton Vance Worldwide Health Sciences Fund 816,790 sh (-12.75%) |
| Lee Ainslie 71,740 sh (New) Steven Cohen 1,098,500 sh (New) Jana Partners 4,724,275 sh (New) PRIMECAP Management 44,720,041 sh (+1.92%) David Carlson 870,000 sh (+16.00%) | Eaton Vance Worldwide Health Sciences Fund 816,790 sh (unchged) | Joel Greenblatt Sold Out John Hussman Sold Out Caxton Associates Sold Out Vanguard Health Care Fund 38,541,504 sh (-3.71%) Dodge & Cox 238,355 sh (-5.92%) Michael Price 277,500 sh (-2.36%) David Tepper 3,910,738 sh (-18.23%) Paul Tudor Jones 26,687 sh (-86.36%) Jim Simons 1,094,305 sh (-4.54%) Diamond Hill Capital 2,999,394 sh (-0.82%) Pioneer Investments 842,727 sh (-1.39%) Mario Gabelli 331,409 sh (-26.83%) Ray Dalio 100,850 sh (-42.72%) |
| Leucadia National 25,000 sh (New) Joel Greenblatt 59,660 sh (New) PRIMECAP Management 44,807,141 sh (+0.19%) Steven Cohen 1,469,300 sh (+33.76%) Paul Tudor Jones 30,623 sh (+14.75%) Pioneer Investments 2,631,078 sh (+212.21%) | David Carlson 870,000 sh (unchged) Eaton Vance Worldwide Health Sciences Fund 816,790 sh (unchged) | Lee Ainslie Sold Out Ray Dalio Sold Out Jim Simons Sold Out Vanguard Health Care Fund 35,049,014 sh (-9.06%) Dodge & Cox 211,955 sh (-11.08%) Michael Price 102,500 sh (-63.06%) David Tepper 2,528,138 sh (-35.35%) Diamond Hill Capital 2,912,581 sh (-2.89%) Mario Gabelli 312,064 sh (-5.84%) Jana Partners 3,137,513 sh (-33.59%) |
| Andreas Halvorsen 3,156,001 sh (New) Caxton Associates 6,499 sh (New) Pioneer Investments 2,957,038 sh (+12.39%) Steven Cohen 3,059,927 sh (+108.26%) | David Carlson 870,000 sh (unchged) Diamond Hill Capital 2,912,535 sh (unchged) | Michael Price Sold Out Leucadia National Sold Out Paul Tudor Jones Sold Out Eaton Vance Worldwide Health Sciences Fund 735,530 sh (-9.95%) Vanguard Health Care Fund 31,396,514 sh (-10.42%) Mario Gabelli 237,764 sh (-23.81%) PRIMECAP Management 44,767,785 sh (-0.09%) Jana Partners 1,974,819 sh (-37.06%) David Tepper 853,875 sh (-66.23%) Joel Greenblatt 9,915 sh (-83.38%) Dodge & Cox 204,255 sh (-3.63%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Medical Devices » Medical Devices NAICS: 339112 SIC: 3841 | |
|---|---|---|
| Compare: | NAS:ISRG, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NYSE:SYK, NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B, NAS:IART, OCSE:GN » details | |
| Traded in other countries: | BSX.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PE Ratio | 78.17 |
BSX's PE Ratio is ranked lower than
98% of the 180 Companies in the Global Medical Devices industry. ( Industry Median: 30.17 vs. BSX: 78.17 ) Ranked among companies with meaningful PE Ratio only. |
BSX'
s PE Ratio Range Over the Past 10 Years
Min: 13.87 Med: 60.59 Max: 435 Current: 78.17 |
| Forward PE Ratio | 23.04 |
BSX's Forward PE Ratio is ranked higher than
71% of the 52 Companies in the Global Medical Devices industry. ( Industry Median: 25.06 vs. BSX: 23.04 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
| PE Ratio without NRI | 78.17 |
BSX's PE Ratio without NRI is ranked lower than
98% of the 179 Companies in the Global Medical Devices industry. ( Industry Median: 30.17 vs. BSX: 78.17 ) Ranked among companies with meaningful PE Ratio without NRI only. |
BSX'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87 Med: 60.59 Max: 435 Current: 78.17 |
| Price-to-Owner-Earnings | 52.04 |
BSX's Price-to-Owner-Earnings is ranked lower than
83% of the 104 Companies in the Global Medical Devices industry. ( Industry Median: 32.03 vs. BSX: 52.04 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. |
BSX'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58 Med: 51.35 Max: 985.26 Current: 52.04 |
| PB Ratio | 6.14 |
BSX's PB Ratio is ranked lower than
70% of the 310 Companies in the Global Medical Devices industry. ( Industry Median: 3.06 vs. BSX: 6.14 ) Ranked among companies with meaningful PB Ratio only. |
BSX'
s PB Ratio Range Over the Past 10 Years
Min: 0.59 Med: 2.22 Max: 6.44 Current: 6.14 |
| PS Ratio | 5.32 |
BSX's PS Ratio is ranked lower than
59% of the 294 Companies in the Global Medical Devices industry. ( Industry Median: 3.15 vs. BSX: 5.32 ) Ranked among companies with meaningful PS Ratio only. |
BSX'
s PS Ratio Range Over the Past 10 Years
Min: 1.02 Med: 2.23 Max: 5.58 Current: 5.32 |
| Price-to-Free-Cash-Flow | 74.83 |
BSX's Price-to-Free-Cash-Flow is ranked lower than
61% of the 107 Companies in the Global Medical Devices industry. ( Industry Median: 26.44 vs. BSX: 74.83 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
BSX'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21 Med: 22.86 Max: 220 Current: 74.83 |
| Price-to-Operating-Cash-Flow | 52.71 |
BSX's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 127 Companies in the Global Medical Devices industry. ( Industry Median: 20.01 vs. BSX: 52.71 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
BSX'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75 Med: 16.81 Max: 62.72 Current: 52.71 |
| EV-to-EBIT | 36.12 |
BSX's EV-to-EBIT is ranked lower than
73% of the 174 Companies in the Global Medical Devices industry. ( Industry Median: 24.76 vs. BSX: 36.12 ) Ranked among companies with meaningful EV-to-EBIT only. |
BSX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5167.6 Med: -3.1 Max: 317.6 Current: 36.12 |
| EV-to-EBITDA | 26.49 |
BSX's EV-to-EBITDA is ranked lower than
69% of the 188 Companies in the Global Medical Devices industry. ( Industry Median: 18.14 vs. BSX: 26.49 ) Ranked among companies with meaningful EV-to-EBITDA only. |
BSX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1 Med: 14.55 Max: 242.5 Current: 26.49 |
| EV-to-Revenue | 5.93 |
BSX's EV-to-Revenue is ranked lower than
62% of the 309 Companies in the Global Medical Devices industry. ( Industry Median: 3.73 vs. BSX: 5.93 ) Ranked among companies with meaningful EV-to-Revenue only. |
BSX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1 Med: 2.9 Max: 6.3 Current: 5.93 |
| Current Ratio | 0.78 |
BSX's Current Ratio is ranked lower than
94% of the 324 Companies in the Global Medical Devices industry. ( Industry Median: 2.71 vs. BSX: 0.78 ) Ranked among companies with meaningful Current Ratio only. |
BSX'
s Current Ratio Range Over the Past 10 Years
Min: 0.52 Med: 1.55 Max: 7.77 Current: 0.78 |
| Quick Ratio | 0.56 |
BSX's Quick Ratio is ranked lower than
93% of the 324 Companies in the Global Medical Devices industry. ( Industry Median: 2.03 vs. BSX: 0.56 ) Ranked among companies with meaningful Quick Ratio only. |
BSX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.33 Med: 1.17 Max: 6.29 Current: 0.56 |
| Days Inventory | 141.74 |
BSX's Days Inventory is ranked higher than
50% of the 294 Companies in the Global Medical Devices industry. ( Industry Median: 143.61 vs. BSX: 141.74 ) Ranked among companies with meaningful Days Inventory only. |
BSX'
s Days Inventory Range Over the Past 10 Years
Min: 116.64 Med: 135.91 Max: 159.64 Current: 141.74 |
| Days Sales Outstanding | 59.64 |
BSX's Days Sales Outstanding is ranked higher than
58% of the 276 Companies in the Global Medical Devices industry. ( Industry Median: 69.21 vs. BSX: 59.64 ) Ranked among companies with meaningful Days Sales Outstanding only. |
BSX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51 Med: 61.98 Max: 66.79 Current: 59.64 |
| Days Payable | 58.49 |
BSX's Days Payable is ranked higher than
60% of the 261 Companies in the Global Medical Devices industry. ( Industry Median: 58.34 vs. BSX: 58.49 ) Ranked among companies with meaningful Days Payable only. |
BSX'
s Days Payable Range Over the Past 10 Years
Min: 24.12 Med: 34.67 Max: 72.7 Current: 58.49 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.10 |
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 244 Companies in the Global Medical Devices industry. ( Industry Median: -5.70 vs. BSX: -1.10 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
BSX'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9 Med: -1 Max: 4.6 Current: -1.1 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 3.66 | ||
| Price-to-Median-PS-Value | 2.38 |
BSX's Price-to-Median-PS-Value is ranked lower than
86% of the 237 Companies in the Global Medical Devices industry. ( Industry Median: 1.02 vs. BSX: 2.38 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
BSX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48 Med: 1.49 Max: 4.28 Current: 2.38 |
| Earnings Yield (Greenblatt) % | 2.77 |
BSX's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 332 Companies in the Global Medical Devices industry. ( Industry Median: 0.74 vs. BSX: 2.77 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
BSX'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.3 Med: 0.3 Max: 9.1 Current: 2.77 |
| Forward Rate of Return (Yacktman) % | -15.78 |
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 125 Companies in the Global Medical Devices industry. ( Industry Median: 6.60 vs. BSX: -15.78 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. |
BSX'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.78 Med: 6.1 Max: 15.4 Current: -15.78 |
| Revenue (TTM) (Mil) $ | 9,670.00 |
|---|---|
| EPS (TTM) $ | 0.47 |
| Beta | 0.96 |
| Volatility | 19.89% |
| 52-Week Range $ | 24.79 - 39.44 |
| Shares Outstanding (Mil) | 1,383.80 |
| Dec18 | Dec19 | Dec20 | Dec21 | |
|---|---|---|---|---|
| Revenue (Mil $) | 9,824 | 10,600 | 11,541 | 12,290 |
| EBIT (Mil $) | 2,146 | 2,499 | 3,176 | |
| EBITDA (Mil $) | 3,006 | 3,412 | 4,199 | |
| EPS ($) | 1.21 | 1.38 | 1.53 | 1.61 |
| EPS without NRI ($) | 1.21 | 1.38 | 1.53 | 1.61 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | 40.61% | |||
| Dividends per Share ($) | ||||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP